Pharsight

Osphena patents expiration

OSPHENA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566252 DUCHESNAY Method for the alleviation of dyspareunia in women
Nov, 2022

(10 months ago)

US9241915 DUCHESNAY Method for enhancing the bioavailability of ospemifene
Feb, 2024

(4 months from now)

US8470890 DUCHESNAY Method for enhancing the bioavailability of ospemifene
Feb, 2024

(4 months from now)

US8772353 DUCHESNAY Method for enhancing the bioavalability of ospemifene
Feb, 2024

(4 months from now)

US9855224 DUCHESNAY Method for enhancing the bioavailability of ospemifene
Feb, 2024

(4 months from now)

US6245819 DUCHESNAY Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
Jul, 2025

(1 year, 9 months from now)

US8236861 DUCHESNAY Method for enhancing the bioavailablity of ospemifene
Aug, 2026

(2 years from now)

US8642079 DUCHESNAY Solid formulations of ospemifene
Jul, 2028

(4 years from now)

Osphena is owned by Duchesnay.

Osphena contains Ospemifene.

Osphena has a total of 8 drug patents out of which 1 drug patent has expired.

Expired drug patents of Osphena are:

  • US9566252

Osphena was authorised for market use on 26 February, 2013.

Osphena is available in tablet;oral dosage forms.

Osphena can be used as treatment of dyspareunia associated with menopause; treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene, treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; treatment of dyspareunia associated with menopause, treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; treatment of dyspareunia associated with menopause; treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene, treatment of dyspareunia associated with menopause, treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene; treatment of dyspareunia associated with menopause, treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene; treatment of dyspareunia associated with menopause; treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause.

The generics of Osphena are possible to be released after 09 July, 2028.

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Jan 25, 2022

Drugs and Companies using OSPEMIFENE ingredient

Market Authorisation Date: 26 February, 2013

Treatment: Treatment of dyspareunia associated with menopause; Treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene; Treatment...

Dosage: TABLET;ORAL

How can I launch a generic of OSPHENA before it's drug patent expiration?
More Information on Dosage

OSPHENA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic